Olanrewaju Okusanya

10PUBLICATIONS
77CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 01, 2026
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma.

|Oct 02, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.

Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci

|Jul 01, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Ashley C Woods, E Dianne Pulte, Xin Wang

|Jun 05, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.

Wei Gao, Jiang Liu, Cynthia J Musante

|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD.

Kelly J Norsworthy, Donna R Rivera, Joseph Wynne

|Oct 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.

Ashley C Woods, Kelly J Norsworthy, Moran Choe

Pageof 2

Frequent Collaborators

5 joint publications

Kelly J Norsworthy

5 joint publications

R Angelo de Claro

4 joint publications

Jonathon Vallejo

4 joint publications

Jiang Liu